{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:09:33Z","timestamp":1758046173697,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ando.2015.03.019","type":"journal-article","created":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T09:00:14Z","timestamp":1429779614000},"page":"163-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Benefits and place of calcimimetics in the management of primary hyperparathyroidism"],"prefix":"10.1016","volume":"76","author":[{"given":"Christian","family":"Meier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2015.03.019_bib0055","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.beem.2013.02.006","article-title":"Role of the calcium-sensing receptor in extracellular calcium homeostasis","volume":"27","author":"Brown","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.03.019_bib0060","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/j.ddtec.2012.11.002","article-title":"Allosteric modulators of the extracellular calcium receptor","volume":"10","author":"Nemeth","year":"2013","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.ando.2015.03.019_bib0065","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1210\/jc.2009-2384","article-title":"Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis","volume":"95","author":"Sankaran","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.03.019_bib0070","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.03.019_bib0075","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1530\/EJE-14-0355","article-title":"The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice","volume":"171","author":"Schwarz","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2015.03.019_bib0080","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1210\/jc.2014-1417","article-title":"Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism","volume":"99","author":"Marcocci","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.03.019_bib0085","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1210\/jc.2010-1221","article-title":"Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity","volume":"96","author":"Peacock","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.03.019_bib0090","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study","volume":"94","author":"Peacock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.03.019_bib0095","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1210\/jc.2007-0585","article-title":"Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma","volume":"92","author":"Silverberg","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2015.03.019_bib0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426615000402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426615000402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:47:28Z","timestamp":1757717248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426615000402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0003426615000402"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2015.03.019","relation":{},"ISSN":["0003-4266"],"issn-type":[{"type":"print","value":"0003-4266"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits and place of calcimimetics in the management of primary hyperparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2015.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}